Ticker Details
CorMedix Inc. Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
IPO Date:	May 13, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$583.39M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 4.04%
Avg Daily Range (30 D):	$0.12 | 1.65%
Avg Daily Range (90 D):	$0.18 | 2.14%

Institutional Daily Volume
Avg Daily Volume:	.41M
Avg Daily Volume (30 D):	.96M
Avg Daily Volume (90 D):	1.99M

Trade Size
Avg Trade Size (Sh.):	126
Avg Trade Size (Sh.) (30 D):	89
Avg Trade Size (Sh.) (90 D):	115

Institutional Trades
Total Institutional Trades:	964
Avg Institutional Trade:	$1.44M
Avg Institutional Trade (30 D):	$1.1M
Avg Institutional Trade (90 D):	$1.29M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$1.75M
Avg Closing Trade (30 D):	$1.04M
Avg Closing Trade (90 D):	$1.47M
Avg Closing Volume:	185.56K

News

Dec 24, 2025 @ 8:42 AM CorMedix Builds a Real Revenue Story as DefenCath ... Source: Nathan Reiff

Nov 21, 2025 @ 2:00 PM American Kidney Fund Hosts Third Patient Access In... Source: Lavarne A. Burton

Nov 12, 2025 @ 4:00 PM Strong Earnings and Biotech Resilience Define the ... Source: Na

Sep 29, 2025 @ 12:30 PM CorMedix Announces Completion of Enrollment in Pha... Source: Globe Newswire

Sep 2, 2025 @ 11:30 AM CorMedix Completes Acquisition of Melinta Therapeu... Source: Globe Newswire

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.25	$.13	$2.25
Diluted EPS	$2.04	$.07	$2.04
Revenue	$311.71M	$128.62M	$311.71M
Gross Profit	$275.75M	$107.31M	$275.75M
Net Income / Loss	$163.06M	$14.02M	$163.06M
Operating Income / Loss	$150.14M	$59.13M	$150.14M
Cost of Revenue	$22.09M	$11.17M	$22.09M
Net Cash Flow	$105.07M	$96.34M	$105.07M
PE Ratio

Splits
Mar 26, 2019	1:5